Nuvation Bio (NYSE:NUVB) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS

Nuvation Bio (NYSE:NUVB) posted its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.04), FiscalAI reports. Nuvation Bio had a negative net margin of 102.06% and a negative return on equity of 44.10%. The company had revenue of $31.69 million during the quarter, compared to the consensus estimate of $27.03 million.

Here are the key takeaways from Nuvation Bio’s conference call:

• IBTROZI net revenue rose 25% quarter over quarter to $23.2 million, with approximately 160 new patient starts; 85% were in the first-line setting, up from roughly 30% at launch. Management said IBTROZI is now the ROS1 TKI market leader in first-line and overall new patient starts.
• Management highlighted IBTROZI’s reported 90% response rate and 50-month median duration of response in TKI-naive patients, along with low adverse-event discontinuations and no CNS warning on its label. The company believes these characteristics are driving broad adoption across academic, community, and integrated delivery network accounts.
• Nuvation expanded safusidenib development across all major IDH1-mutant glioma segments, including a new Phase III study in newly diagnosed low-grade disease and a Phase II study in patients whose disease progresses after vorasidenib. In updated J201 data, the response rate increased to 52%, while the 36-month progression-free survival rate was 79%.
• The company ended the quarter with $661 million in cash, cash equivalents, and marketable securities and raised approximately $279 million through low-coupon convertible notes. Management said the financing reduced cash interest expense, strengthened strategic flexibility, and should provide sufficient capital to reach profitability and fund the anticipated safusidenib launch.
• Later-line IBTROZI patient additions are slowing as the company has largely worked through the finite pool of pretreated patients, making future growth increasingly dependent on first-line adoption, improved testing, and converting patients who still receive chemotherapy or immunotherapy.

Nuvation Bio Stock Performance

Shares of NYSE NUVB traded down $0.28 during trading hours on Thursday, reaching $6.09. 8,391,554 shares of the stock were exchanged, compared to its average volume of 6,039,828. The firm has a market capitalization of $2.12 billion, a price-to-earnings ratio of -14.16 and a beta of 1.52. The stock’s fifty day simple moving average is $5.72 and its 200 day simple moving average is $5.23. The company has a debt-to-equity ratio of 0.15, a quick ratio of 7.24 and a current ratio of 7.44. Nuvation Bio has a 52 week low of $2.18 and a 52 week high of $9.75.

Insider Transactions at Nuvation Bio

In related news, CFO Philippe Sauvage sold 47,668 shares of the firm’s stock in a transaction on Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total value of $286,484.68. Following the transaction, the chief financial officer owned 12,673 shares in the company, valued at approximately $76,164.73. This trade represents a 79.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Stacy Markel sold 125,000 shares of the business’s stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $6.03, for a total value of $753,750.00. Following the completion of the transaction, the insider directly owned 32,591 shares of the company’s stock, valued at approximately $196,523.73. This trade represents a 79.32% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 235,668 shares of company stock valued at $1,419,495. Company insiders own 30.11% of the company’s stock.

Hedge Funds Weigh In On Nuvation Bio

Hedge funds and other institutional investors have recently made changes to their positions in the company. Millennium Management LLC increased its stake in Nuvation Bio by 52.4% in the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock valued at $6,642,000 after acquiring an additional 1,298,131 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Nuvation Bio by 19.9% during the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company’s stock worth $12,276,000 after purchasing an additional 551,508 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Nuvation Bio by 852.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after purchasing an additional 2,424,109 shares in the last quarter. Two Sigma Investments LP boosted its holdings in shares of Nuvation Bio by 95.7% in the 3rd quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company’s stock valued at $8,797,000 after purchasing an additional 1,162,837 shares in the last quarter. Finally, Armistice Capital LLC increased its stake in shares of Nuvation Bio by 359.2% in the 3rd quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock valued at $8,495,000 after purchasing an additional 1,796,000 shares during the last quarter. 61.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Wedbush reissued an “outperform” rating and issued a $11.00 price objective on shares of Nuvation Bio in a report on Thursday, July 23rd. Truist Financial upped their price target on shares of Nuvation Bio from $12.00 to $13.00 and gave the stock a “buy” rating in a research report on Tuesday, July 7th. Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a research report on Wednesday, June 10th. Zacks Research upgraded shares of Nuvation Bio from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvation Bio in a research report on Friday, July 17th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $12.88.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.